Back to Search Start Over

Asimadoline and its potential for the treatment of diarrhea-predominant irritable bowel syndrome: a review

Authors :
Mangel,Allen W
Hicks,Gareth A
Mangel,Allen W
Hicks,Gareth A
Publication Year :
2012

Abstract

Allen W Mangel1, Gareth A Hicks21RTI Health Solutions, Research Triangle Park, NC, 2Tioga Pharmaceuticals Inc, San Diego, CA, USAAbstract: Irritable bowel syndrome (IBS) is a multifactorial condition with principal symptoms of pain and altered bowel function. The kappa-opioid agonist asimadoline is being evaluated in Phase III as a potential treatment for IBS. Asimadoline, to date, has shown a good safety profile and the target Phase III population – diarrhea-predominant IBS patients with at least moderate pain – was iteratively determined in a prospective manner from a Phase II dose-ranging study. The clinical data in support of this population are reviewed in this article. Furthermore, the scientific rationale for the use of asimadoline in the treatment of IBS is reviewed. Considering the high patient and societal burdens of IBS, new treatments for IBS represent therapeutic advances.Keywords: irritable bowel syndrome, kappa-opioid agonist, asimadoline, visceral pain, visceral hypersensitivity&nbsp

Details

Database :
OAIster
Notes :
text/html, English
Publication Type :
Electronic Resource
Accession number :
edsoai.ocn953562977
Document Type :
Electronic Resource